Seres Therapeutics Inc (NASDAQ:MCRB) Reports Q2 2025 Earnings: Narrower EPS Loss but Shares Dip in Pre-Market

Seres Therapeutics Inc (NASDAQ:MCRB) reported its second-quarter 2025 financial results, posting revenue of $0.0 and an earnings per share (EPS) loss of $2.27. While revenue was in line with analyst expectations, the company’s EPS outperformed estimates, which had projected a deeper loss of $2.54. Despite the narrower-than-expected loss, shares traded down approximately 4.5% in pre-market activity, suggesting investor skepticism or profit-taking following recent gains—the stock has risen 23% over the past month.

Key Financial Takeaways

• Revenue: Reported $0.0, matching analyst estimates.
• EPS: Posted a loss of $2.27, better than the anticipated $2.54 loss.
• Market Reaction: Pre-market decline of ~4.5%, despite outperforming EPS expectations.
• Recent Performance: The stock has gained 23% over the past month, potentially leading to some consolidation.

Business Updates from the Press Release

The company highlighted progress in its clinical pipeline, particularly for SER-155, a live biotherapeutic candidate aimed at preventing bloodstream infections (BSIs) in patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT). Following discussions with the FDA, Seres has submitted a Phase 2 study protocol for SER-155, which previously demonstrated promising results in a Phase 1b trial. The drug has also received Fast Track designation from the FDA, underscoring its potential to address unmet medical needs in high-risk patient populations.

Outlook vs. Analyst Estimates

The press release did not provide forward-looking financial guidance, making it difficult to assess whether the company’s internal projections align with analyst expectations. For the full year 2025, analysts estimate revenue of $0.0 and an EPS loss of $1.71. For Q3 2025, revenue is projected at $0.0 with a slight EPS improvement to -$0.03. The lack of company-provided guidance may contribute to market uncertainty, explaining the muted reaction despite the earnings beat.

Market Sentiment and Next Steps

The pre-market dip could reflect broader market conditions, sector-specific headwinds, or simply a pullback after recent gains. Investors will likely focus on upcoming clinical milestones for SER-155, as further positive data could drive long-term optimism.

For more detailed earnings estimates and historical performance, see Seres Therapeutics’ earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.